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 Clinical Characteristics at Onset Background Hematologic Results 
We seek to determine whether GCSF+IVIG augmented standard of care 
improves survival & expedites recovery vs standard of care therapy (SRx) 
alone in preterm neonates (<37 wks) with pneumatosis (Bell Stage II). 
Objectives 
• IRB approved, parent consented, single center prospective, RCT of any 
preterm neonate who developed NEC at our  NICU since Oct 2011.  
• Neonates are randomly assigned to either SRx or treated with GCSF (10 
mcg/kg/d) and IVIG (500 mg/kg/d) IV x 3d along with SRx.  
• The primary outcome is survival to one month or the ability to attain full 
enteral feeds within 3 weeks of antibiotics.  
• Serial blood counts are monitored on days 0, 1, 2, 3 & 7-10d.  
• RCT interim safety analysis was done by paired t-test and chi-square.  
• The incidence of necrotizing enterocolitis (NEC) is < 15% in ELBW 
neonates & is associated with > 25% mortality; medical management has 
not changed for the past 40 yrs. 
• GCSF increases the absolute neutrophil count, improves neutrophil 
function (↑ Fc & C’ receptor density) and lowers TNFα. 
• IVIG improves phagocytosis, oxidative burst and opsonization activity.  
• GCSF induced phagocytosis improves further in vitro when opsonized 
with IgG, we hypothesized that combining the interventions will improve 
neonatal outcomes with Bell stage II NEC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
   
 
Standard  
n=12 
Treated  
n=17 
Surgery %(n) 50 (6) 35 (6) 
Death at 1 week %(n) 8 (1) 12 (2) 
Death at 1wk- 1 month 0 0 
Days to full feeds after NEC 
mean + sd (median) 16 + 7 (13 ) 21 + 17 (14.5 ) 
Full feeds  within 3 wks of 
antibiotics %(n) 83 (10) 71 (12) 
Primary outcome  
(Survival or attain full feeds 
within 3weeks) %(n) 
92 (11) 88 (15) 
Time discharge (days) mean + 
sd  (median)  91 + 37 (83) 102 + 42 (108) 
Methods 
Demographics 
  
Conclusions 
• There was no increase in complications (ROP,IVH,PVL and death) 
indicating the trial can continue. We plan to sustain enrollment to reach 
the desired goal of 25 subjects in each group. 
• In the interim analysis we have not found statistically significant 
differences in our primary outcome. 
• GCSF+IVIG increased WBC and ANC significantly even in critically ill 
neonates, rate of rise more then standard treatment.  
•  No effect on platelet and lymphocyte counts in either group.  
   Standard  
n=12 
Treated 
n=17 
Gestational Age (wks) 
Mean ± SEM 
 (median, Min-Max) 
27 ± 0.5 
(27, 25-30)  
28 ± 0.7 
(28, 24-34) 
Birth weight (g) 1017 ± 68 (1005, 600-1510) 
1007 ± 95 
(1030, 430-2120) 
SGA %(n) 0 (0) 24 (4)  
Antenatal Steroids %(n) 83 (10) 82 (14) 
Male %(n) 75 (9) 24 (4)* 
Clinical Outcomes at Discharge 
   
 
Standard  
n=12 
Treated  
n=17 
DOL @ NEC (d) 
Mean  ± SEM 
(Median, min-max) 
20 ± 3.7 
(17, 6-36) 
23 ± 4.9 
(21, 9-64)  
PCA @ NEC (d) 30  ± 0.8 (30, 27-34) 
31  ± 0.8 
(31, 28-37)  
Weight @ NEC (g) 1287  ± 140 (1260, 770-1910) 
1272  ± 129 
(1270, 680-2240) 
Positive blood culture %(n) 8 (1) 12 (2) 
HCT 48hrs prior to NEC  32  ± 1.3 (32, 27-41)  
35  ± 2.7 
(33, 24-57) 
Presence of PDA %(n) 50 (6) 47 (8) 
Treatment with Indomethacin 
%(n) 42 (5) 24 (4) 
Full Oral Feeds %(n) 50 (6) 76 (13) 
Feeding with Formula %(n) 50 (6) 53 (9) 
Ventilator Dependent %(n) 25 (3) 23 (4) 
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